Teladoc Health (NYSE:TDOC) Insider Carlos Nueno Sells 6,196 Shares

Teladoc Health, Inc. (NYSE:TDOC) insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the sale, the insider owned 57,671 shares in the company, valued at $440,029.73. This represents a 9.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Trading Down 6.1%

NYSE TDOC opened at $7.08 on Thursday. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.77. The firm has a market capitalization of $1.28 billion, a PE ratio of -7.30 and a beta of 2.14. The stock’s 50 day moving average is $6.13 and its 200 day moving average is $6.21.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, April 29th. The health services provider reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.01). Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. The firm had revenue of $613.85 million for the quarter, compared to the consensus estimate of $611.04 million. During the same quarter in the prior year, the firm earned ($0.53) earnings per share. The company’s revenue for the quarter was down 2.5% compared to the same quarter last year. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. Research analysts forecast that Teladoc Health, Inc. will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teladoc Health

Several hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Teladoc Health by 4.2% in the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock worth $169,372,000 after acquiring an additional 891,732 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Teladoc Health by 1.3% in the first quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider’s stock worth $44,066,000 after purchasing an additional 107,400 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Teladoc Health by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock worth $52,459,000 after purchasing an additional 605,061 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Teladoc Health by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock worth $29,324,000 after purchasing an additional 18,394 shares during the last quarter. Finally, Jupiter Asset Management Ltd. raised its stake in shares of Teladoc Health by 293.9% in the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after purchasing an additional 2,880,008 shares during the last quarter. 76.82% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TDOC has been the topic of several research reports. Canaccord Genuity Group dropped their price target on Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Barclays dropped their target price on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. TD Cowen dropped their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday, February 26th. Leerink Partners dropped their target price on Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a report on Thursday, February 26th. Finally, Stifel Nicolaus dropped their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $7.43.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.